Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and sex toys.
Popular Articles

Senate Bill To Protect Patients' Healthcare By Amending Medicare Coverage
The U.S. Senate has introduced a bill, S. 1221, "The Medicare Prompt Pay Correction Act," a companion bill to H.R. 1392, which was introduced in the U.S. House of Representatives and currently has 45 co-sponsors.
buy viagra
New Study Reveals Wide Variations In Depression Diagnoses Among Ethnic Groups
Whites experiencing depression are far more likely to be diagnosed by a physician than other ethnic groups, according to a new Consumer Health Sciences (CHS) study presented today at the 14th Annual ISPOR (International Society for Pharmacoeconomic and Outcomes Research) Conference in Orlando, Florida. The study reveals that 76% of whites with self-reported depression symptoms are officially diagnosed, compared to just 58.7% of blacks, 62.7% of Hispanics and 47.4% of Asians.
News of the day
Pluristem Therapeutics Announces First Patient Enrollment In Phase I Clinical Trial For Treatment Of Peripheral Artery Disease With PLX-PAD
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the first patient has been enrolled in a Phase I clinical trial of the Company"s allogeneic placental-derived adherent stromal cell product, termed PLX-PAD. PLX-PAD is being used in patients afflicted with critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The first patient was enrolled at the Franziskus-Krankenhaus Hospital, Berlin. The initiation of this study follows the recent approval of the Company"s Clinical Trial Application (CTA) to begin clinical trials with PLX-PAD by the Paul Ehrlich Institute (PEI), the German competent authority in the European Union. The Phase I study is designed to evaluate the safety of PLX-PAD in patients with CLI. A total of up to fifteen adults with the disease will be included in the trial which is being conducted at the Franziskus-Krankenhaus Hospital and Charitç© - Universitç¤tsmedizin Hospital, Berlin.
Health Insurance

Statement From CCF Against CDC Nominee Thomas Frieden

Following today"s announcement that President Obama nominated Dr. Thomas Frieden to head the Center for Disease Control and Prevention, the Center for Consumer Freedom"s Senior Research Analyst, J. Justin Wilson, released the following statement: "It is unfortunate that President Obama choose to put the nation"s health in the hands of an overzealous activist who doesn"t give any consideration to the importance of personal responsibility or privacy," said Wilson. "Frieden doesn"t simply blur the line between what is the government"s responsibility in regulating health and what is the individual"s responsibility; he barely recognizes its existence." Thomas Frieden famously told the Financial Times that "when anyone dies at an early age from a preventable cause in New York City, it"s my fault." What constitutes a "preventable cause" for Frieden? Essentially any behavior that he personally disapproves of, including: eating salty or fatty foods, "insufficient" breast-feeding, and using birth control that isn"t city-approved. Following his myriad regulations in New York City, the New York Post quipped that Frieden had turned the city into "a nanny state on steroids." The Center for Consumer Freedom


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009